Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 11, 2026Advances in TherapyOpen Access

Real-World Clinical and Economic Consequences of Next-Generation Anaplastic Lymphoma Kinase-Positive (ALK +) Tyrosine Kinase Inhibitors (TKIs) in Patients with TKI-Naïve ALK + Metastatic Non-Small Cell Lung Cancer in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJyoti MalhotraEMElizabeth H. MarchlewiczYZYan Zhang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows no differences in effectiveness or costs among three ALK TKIs in TKI-naïve patients.

Key Points

  • The aim is to assess the utilization, effectiveness, adverse events, and healthcare costs of next-generation ALK TKIs in ALK TKI-naïve metastatic non-small cell lung cancer patients.
  • Retrospective observational cohort study using electronic health records and claims data.
  • Included 481 adult patients diagnosed with ALK + mNSCLC receiving first ALK TKI from 2020 to 2024.
  • Conducted descriptive analyses and Cox proportional hazards models to evaluate treatment effectiveness and healthcare costs.
  • No statistically significant differences in real-world treatment effectiveness metrics (rwTTD, rwTTNT, rwPFS, rwOS) among alectinib, brigatinib, and lorlatinib.
  • Mean all-cause healthcare costs per patient per month were $20,873 for alectinib, $25,693 for brigatinib, and $24,984 for lorlatinib, with no significant differences.
  • Majority demographic included mostly females and patients covered by commercial insurance.

Cite This Study

Malhotra et al. (2026) studied this question.

synapsesocial.com/papers/6a51df9fc18d7f28ca5009e2https://doi.org/10.1007/s12325-026-03679-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer2017 · 2,524 citations
  2. 2Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments2024 · 1 citations
  3. 3Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years2017 · 452 citations
  4. 4Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors2014 · 200 citations
  5. 5Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis2023 · 110 citations